Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Quick start hydroxyurea initiation project (q-ship): targeted education after crisis to increase the use of hydroxyurea in children with sickle cell anemia
source: American Society of Pediatric Hematology/Oncology
year: 2017
authors: Lydia H. Pecker, Baltimore, Sarah Kappa, Deepika Darbari, Robert S. Nickel
summary/abstract:Background:
Sickle cell anemia (SCA) is an inherited hemoglobinopathy characterized by episodic painful crises, progressive multi-organ injury, and early death. Hydroxyurea (HU) is the only FDA-approved disease modifying medicine for SCA. Recent NHLBI guidelines recommend offering HU to all children with SCA. Despite this, many eligible children are not on this treatment. Novel strategies to increase HU use in children with SCA are needed.
Objectives:
To evaluate the effectiveness of an intervention to start HU in children with SCA soon after a disease complication.
Results:
Over 9 months (2/17/2016 – 12/1/2016), 69 eligible patients presented to our ED. 68% (n=47) attended a Q-SHIP session a median of 5 days (IQR 1.5-15.5) after ED or hospital discharge. Median patient age was 8.1 years (IQR 5.0-16.5). Nearly half of participants (parents or patients >18 years old), reported no previous HU offer (49%, n=23/47), but documentation in 69% (n=15/23) of these patients’ charts stated that HU had been offered and declined. Patients/parents who reported a previous HU offer (n=24) had not previously accepted HU due to concern for treatment side effects (n=8), infrequent SCA complications (n=6), and wanting more information (n=6). Post-intervention, 51% of patients (n=24/47) started HU. The intervention was equally effective for participants who reported a previous HU offer compared to those who reported no previous offer (13/24, 54%, vs. 11/23, 48%, p=0.66). At follow-up (median 5.5 months, IQR 1.9-7.6), 91% of patients (n=22/24) who started HU after Q-SHIP continued taking it.
Conclusion:
Targeted HU education for patients who recently suffered a SCA complication led to HU initiation in over half of participants. This raises the intriguing possibility that intervention after an acute SCA complication will increase parent/patient HU acceptance. Surprisingly, many parents/patients reported no prior HU offer despite documentation to the contrary. This may reflect an unappreciated communication barrier between parents/patients and providers that requires further study.
+myBinderRelated Content
-
Shakir Cannon, advocate for minority health, diesShakir Lateef Cannon, a 34-year-old advo...
-
N-acetylcysteine in Patients with Sickle Cell Disease: A Randomized Controlled TrialPatients with sickle cell disease (SCD) ...
-
2023 NHLBI Annual Sickle Cell Disease Research MeetingSave the Date for the NHLBI Annual Sickl...
-
Nadia Ewing, MDNadia Ewing, M.D., is a clinical profess...
-
Webinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
-
Today’s Faces of Sickle Cell Disease: Tanielle RandallIt was not until their daughter was born...
-
Spectra Optia for automatic red blood cell exchange in patients with sickle cell diseaseThis guidance represents the view of NIC...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.